Quell Therapeutics

Quell Therapeutics is a world leader in the development of engineered T-regulatory (Treg) cell therapies, aiming to harness, direct, and optimize their immunosuppressive properties to address serious medical conditions driven by the immune system. The company is leveraging its groundbreaking phenotype-locking technology, unique multi-module platform, and integrated manufacturing capabilities to design and develop a range of highly engineered Treg cell therapies, which have greater potential in terms of stability, persistence, and potency compared to previous generations of Treg cell therapy approaches. Quell’s lead candidate, QEL-001, is being developed to induce operational tolerance after liver transplantation, with the potential to protect the transplanted liver without the long-term use of immunosuppressive drugs. Quell is also advancing other programs in neuroinflammation and autoimmune diseases.